[The chronic bronchitis syndrome. New pathogenetic and therapeutic aspects].
D000890:Anti-Infective Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications; D001991:Bronchitis / Q000209:etiology / Q000235:genetics / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D002908:Chronic Disease; D002980:Climate; D003550:Cystic Fibrosis / Q000150:complications; D003902:Detergents / Q000627:therapeutic use; D005100:Expectorants / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D010102:Oxygen Inhalation Therapy; D010276:Parasympatholytics / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D012140:Respiratory Tract Diseases / Q000150:complications; D012141:Respiratory Tract Infections / Q000150:complications; D012852:Sinusitis / Q000150:complications; D012907:Smoking; D013566:Sympathomimetics / Q000627:therapeutic use; D013577:Syndrome
D000890:Anti-Infective Agents; D000925:Anticoagulants; D003902:Detergents; D005100:Expectorants; D006993:Hypnotics and Sedatives; D010276:Parasympatholytics; D013566:Sympathomimetics
Das chronisch-bronchitische Syndrom. Neue pathogenetische und therapeutische Aspekte.